MFN News Items – Page 6

iZafe Group Q2 Interim Report, April-June 2023

iZafe Group AB (publ.) presents today, August 25, its report for the second quarter.

Financial Performance in Summary

Net sales for the quarter amounted to SEK 403 (84) thousand, a growth of 380% compared to the corresponding quarter last year. The increase in turnover can partly be attributed to organic growth, partly to growth through acquisition, when Pilloxa was acquired in December 2022. Excluding the turnover from the acquired company, the growth amounted to 198%. The quarter’s turnover consists of income attributable to the sale of the digital pharmaceutical robot Dosell and the sale of the medical device Pilloxa. Pilloxa AB was acquired on 28 November 2022 and is therefore not included in the quarter’s turnover for the previous year.
Operating profit for the quarter amounted to SEK -5,097 (-5,184) thousand.
Profit after financial items for the quarter amounted to -5,136 (-5,233) TSEK.
Cash flow for the period amounted to SEK -3,496 (-7,155) thousand.
Earnings per share for the quarter before / after dilution amounted to SEK 0.0 (-0.1).
Equity per share amounted to SEK 0.2 (0.4) at the end of the period.
The equity ratio at the end of the period amounted to 82.4 (81.8) percent.

Significant events during the quarter

iZafe has signed a cooperation agreement with Spanish Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi’s minimum commitment over a four-year period is worth at least SEK 12 million.
iZafe has signed a cooperation agreement with MDM Pulse for the right to sell and market the medicine robot Dosell in Portugal. MDM Pulse’s minimum commitment over a five-year period amounts to SEK 12.2 million to subsequently generate a recurring license income of at least SEK 4.2 million annually.

Significant events after the end of the quarter

iZafe successfully completed all necessary technical integrations and adaptations to launch Dosell on the Dutch market. The company will now deliver 50 units for testing. After successful testing, the remaining 1,000 units will be delivered successively during the year.

Comments from CEO
I am pleased to share with you the latest progress and developments in our company during the past quarter. Despite an initially low turnover, our focus on the right strategies and measures has resulted in a positive increase in our turnover. This increase, although it may be modest, marks a turning point in the right direction. Together with our continuous effort to streamline and reduce costs, we now stand on a stable foundation.

I feel confident that the liquidity we obtained in March will be sufficient to bring us to a cash flow positive position. Our determination to optimize our finances and capital utilization has set us on this promising path forward. I would like to express my heartfelt thanks to you for your continued trust and investment in our company. Your faith in us has been a decisive factor in our success.

During the first half of the year, we communicated about several significant orders that lie ahead. Now our top priority is to ensure that the deliveries of these orders are carried out smoothly. One of our most challenging tasks is to deliver 1,000 units to the Netherlands before the end of this year. The first 50 units will be used to guarantee a seamless customer experience with our innovative solution, uniquely tailored to the needs of the Dutch market. The setup is a result of our joint work with investments from both the partner, Dutch IVE Ventures, and us, where IVE Ventures invested in a comprehensive system where Dosell has a key function. Tests are currently underway and are expected to be completed shortly. When potentially needed fine adjustments in the customized system solution are in place after feedback from the tests, we will gradually deliver the remaining units according to plan.

We also see positive progress in Spain, where plans are progressing as previously communicated. During Q2, an agreement worth minimum SEK 12 million over four years was secured, including 1,800 Dosell units. The Spanish partner Ti-Medi delivers today solutions to facilitate correct medication to over 650 pharmacies in Spain and Portugal. During the autumn, we are working intensively to adapt Dosell and the customer journey for the Spanish market, which will hopefully lead to an extensive launch during the first quarter of 2024.

Also in Italy we have worked further to develop our collaborations. Our partner has been working for some time to achieve a wider acceptance of sachets in the Italian market. They are currently conducting a funding round to secure the necessary capital to accelerate sales of our pharmaceutical robots along with their innovative sachets on a larger scale.

In the UK, we are on the verge of completing our first pilot, which is a milestone for us. This marks the start of gradually increasing sales that are expected to pick up from the turn of the year. The UK is a market with huge potential, and we foresee steady growth as the market matures.

In our home region, the Nordics, our work with municipalities in Sweden and Norway has yielded results. The decision to expand the use of Dosell within these municipalities is a clear indication that our product is appreciated for its simplicity, functionality and its ability to relieve care by ensuring correct medication at the right time. I am optimistic that we will see increasing demand also here in the Nordics during the autumn, and a positive trend that is expected to grow significantly in the coming year.

Our latest acquisition, Pilloxa, has added additional value to our portfolio. Our focus now is on ensuring customer satisfaction through smooth deliveries and maximizing the potential of our new customers. Going forward, we aim to merge our concepts into a world-unique concept that can help the patient at all stages; regardless of how they manage their medication, but right now our primary focus is on ensuring that Dosell deliveries to our partners around Europe.

In summary, we are stronger and more well prepared than ever. With a stable liquidity that is expected to bring us to a cash flow positive position, together with the majority of orders received and a growing demand, we are enthusiastically looking forward to the upcoming autumn. I am convinced that, together with my amazing team, we will be able to achieve outstanding results.

Again, many thanks for your invaluable trust as a shareholder.

Anders Segerström
CEO, iZafe Group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution and the connected dose bag Pilloxa. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Interim Report Q2 2023

Intervju Q2 2023 iZafe Group

Omslagsbild Q2 2023

iZafe Group’s new identity is launched to clarify the company’s vision

iZafe group AB (publ.) is proud to present an exciting new development in the company's identity and expression. With the goal of further strengthening its presence on the international scene, the company is today launching an updated logo and design, in parallel with the launch of a new website that is in both Swedish and English.

iZafe's current logo and color language were developed when the company focused on both safety and health. iZafe implements this change to better reflect the company's current vision and direction and make it easier for owners and other stakeholders to get a correct and comprehensive picture of where the company stands and is headed.
The new design captures the company's dedication to developing digital products to ensure the right medication at the right time, while standing as a symbol of precision and care for each individual patient.

At the center of the new logo is a subtle pill shape, surrounded by rings reminiscent of fingerprints. This design highlights the uniqueness of the individual and the company's focus on patients. The clean and elegant lines radiate efficiency and streamlined operations, demonstrating the simplicity and convenience of the automated products and services. The rings expand from the pill like ripples on the water and symbolize change and transformation. The technological elements are emphasized by node-like line endings.

The new logo is complemented by a clean and modern typography, which harmoniously enhances the simplicity and style of the design.

In connection with iZafe receiving great interest internationally, the website is being launched in both Swedish and English and is designed to give visitors a deeper insight into the company's innovative work and commitment to patient safety and medical adherence.

"With the new logo and design, we are taking a powerful step into the future. We are strengthening our commitment to being the leading player in digital services for correct medication. This change reflects our determination to streamline our focus and corporate profile towards our core business. We are ready to shape a new era where we become the natural partner for healthcare companies globally, and our goal is clear – to help people stay healthy and live longer in their own homes.” says Anders Segerström, CEO iZafe Group.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group's new identity is launched to clarify the company's vision

Förklaring Ikon

The Chairman of iZafe Group, Björn Rosengren, acquires an additional 500,000 shares

Today, the Chairman of iZafe Group, Björn Rosengren, has acquired 500,000 Class B shares in the company, valued at 110,000 SEK (0.22 SEK per share.

In addition to today's transaction, Björn Rosengren also acquired 50,000 A-shares last week. Björn Rosengren now holds a total of 2,960,319 B-shares and 50,000 A-shares.

"I am pleased to increase my ownership in iZafe Group, which reflects my belief in the company's vision and potential," says Björn Rosengren. "These acquisitions demonstrate my continued commitment to supporting iZafe Group's strategic goals and creating value for its shareholders."

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafe.se/investor-relations/.

The Chairman of iZafe Group, Björn Rosengren, acquires an additional 500,000 shares

iZafe Group AB ready for the implementation of Dosell in the Netherlands following successful integrations

iZafe Group AB ("iZafe Group") announces today that the company has successfully completed all necessary technical integrations and adaptations to launch its groundbreaking medication robot, Dosell, in the Dutch market. These adaptations have included both technical adjustments in the Dosell device and platform, as well as extensive developments and customizations from our partner.

As a significant step forward, iZafe Group will now deliver 50 Dosell units to test the new customer journey in practice for one month. This phase of the pilot program will contribute to ensuring a smooth launch and customer experience. Following successful testing, the remaining 1,000 units will be delivered gradually throughout the rest of the year, according to the previously communicated plan.

"We are delighted to be part of this collaboration with iZafe Group for the launch of Dosell in the Dutch market. Dosell offers a groundbreaking digital medication robot that complements our existing portfolio of connected healthcare services. We are confident that Dosell will provide a reliable and secure alternative for the medication needs of our healthcare and alarm center clients in the Netherlands. Together, we can fulfill our shared mission of promoting independence and security in the simplest, safest, and most cost-effective way," says Martijn Van Bree, CEO of IVE Ventures.

"We are very pleased to have completed the technical integrations and adaptations for the launch of Dosell in the Dutch market. This marks a significant milestone for us and opens doors to a market known for its commitment to medication in pouches. The selection of Dosell by IVE Ventures after careful evaluation of competitors confirms the great potential of our product on the international stage. We look forward to collaborating with IVE and enabling a safe and efficient medication experience for their clients," says Anders Segerström, CEO of iZafe Group AB.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB ready for the implementation of Dosell in the Netherlands following successful integrations

iZafe Group presenterade på Aktiespararnas Småbolagsdagar

iZafe Groups VD Anders Segerström presenterade bolaget på Aktiespararnas evenemang Småbolagsdagarna den 12 juni. Presentationen innehåller bland annat uppdateringar kring dom nya internationella försäljningarna och status kring förvärvet av Pilloxa.

Presentationen kan du se här
Du hittar även denna presentation samt tidigare presentationer på: https://izafe.se/presentationer/

Om iZafe Group AB (publ.)

iZafe Group är ett Life Science bolag som bedriver forskning,utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet.

Bolaget leder utvecklingen av digital läkemedelsdispensering genom läkemedelsroboten Dosell samt Saas-lösningen och den uppkopplade dosettasken Pilloxa. Bolagets lösningar minskarrisken för felmedicinering i hemmet, ökar följsamheten, avlastar den offentliga vården, ökar livskvaliteten för patienter samt skapar en tryggare miljö för anhöriga.

Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitterlånga och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

iZafe Group AB är noterat på Nasdaq First North Growth Market sedan 2018. Mangold Fondkommission AB är bolagets Certified Adviser. Ytterligare information finns på www.izafe.se/investor-relations/.

iZafe Group presenterade på Aktiespararnas Småbolagsdagar

Kommuniké från extra årsstämma i iZafe Group AB

Årsstämman i iZafe Group AB, org. nr 556762–3391, ("Bolaget"), ägde rum idag tisdagen den 16 maj 2023 i Bolagets lokaler på David Bagares Gata 3, Stockholm. Årsstämman beslutande, bland annat följande:

Fastställande av resultat- och balansräkning
Stämman fastställde resultat- och balansräkningen för moderbolaget och koncernen för räkenskapsåret 2022.

Utdelning
Stämman beslutade att ingen utdelning lämnas och att årets resultat balanseras i ny räkning.

Ansvarsfrihet
Stämman beviljade styrelseledamöterna och verkställande direktören ansvarsfrihet för räkenskapsåret 2022.

Styrelse och revisor samt arvodering
Stämman beslutade att antalet styrelseledamöter ska bestå av fem (5) av stämman valda ordinarie ledamöter utan suppleanter och att antalet revisorer ska uppgå till en auktoriserad revisor utan suppleanter. Årsstämman beslutade om omval av styrelseledamöterna Magnus Engman, Göran Hermansson, Richard Wolff, Bosse Johansson och Björn Rosengren. Björn Rosengren valdes till styrelseordförande. Den auktoriserade revisorn Johan Kaijser omvaldes till Bolagets revisor för tiden intill nästa årsstämma.

Stämman fastställde inget styrelsearvode ska utgå till ordinarie ledamöter eller till styrelseordförande. Revisorn erhåller ersättning enligt löpande räkning.

Ändring av bolagsordningen
Stämman beslutade om ändring av bolagsordningen på så sätt att aktiekapitalet ska uppgå till lägst 50 000 000 kronor och högst 200 000 000 kronor och antalet aktier ska vara lägst 250 000 000 och högst 1 000 000 000 aktier.

Bemyndigande för styrelsen att besluta om emissioner aktier, teckningsoptioner och konvertibler
Stämman beslutade att bemyndiga styrelsen att – vid ett eller flera tillfällen och längst intill nästkommande årsstämma – besluta om att öka Bolagets aktiekapital genom nyemission av aktier samt att emittera teckningsoptioner och konvertibler motsvarande högst tjugo (20) procent av det totala antalet utestående aktier i Bolaget vid den tidpunkt då styrelsen första gången utnyttjar bemyndigandet.

Nyemission av aktier, liksom emission av teckningsoptioner och konvertibler, ska kunna ske med eller utan avvikelse från aktieägarnas företrädesrätt samt med eller utan bestämmelse om apport, kvittning eller andra villkor. Enligt 16 kap. aktiebolagslagen äger styrelsen inte med stöd av detta bemyndigande besluta om emissioner till styrelseledamöter i koncernen, anställda med flera.

Beslut om bemyndigande till styrelsen att vidta mindre justeringar av de på stämman fattade besluten
Årsstämman beslutade att bemyndiga styrelsen, den verkställande direktören eller den styrelsen i övrigt förordnar att vidta sådana smärre justeringar och förtydliganden av besluten tagna på stämman i den utsträckning detta är erforderligt för registrering av besluten.

Om iZafe Group AB (publ.)

iZafe Group är ett Life Science bolag som bedriver forskning,utveckling och marknadsföring av digitala medicinska lösningar och tjänster för tryggare läkemedelshantering i hemmet.

Bolaget leder utvecklingen av digital läkemedelsdispensering genom läkemedelsroboten Dosell samt Saas-lösningen och den uppkopplade dosettasken Pilloxa. Bolagets lösningar minskarrisken för felmedicinering i hemmet, ökar följsamheten, avlastar den offentliga vården, ökar livskvaliteten för patienter samt skapar en tryggare miljö för anhöriga.

Kunderna utgörs av privatpersoner, läkemedelsbolag samt offentliga och privata vårdgivare i Sverige, Norden och globalt. iZafe Group säljer primärt via väletablerade partners som redan besitterlånga och djupa kundrelationer med de prioriterade kundgrupperna. Huvudkontoret ligger i Stockholm.

iZafe Group AB är noterat på Nasdaq First North Growth Market sedan 2018. Mangold Fondkommission AB är bolagets Certified Adviser. Ytterligare information finns på www.izafe.se/investor-relations/.

Kommuniké från extra årsstämma i iZafe Group AB

iZafe Group Q1 Interim Report, January-March 2023

iZafe Group AB (publ.) presents today, May 12, its report for the first quarter.

Financial Performance in Summary

The net revenue for the quarter amounted to 228 (376) TSEK. The revenue for the quarter consists of income related to sales of the digital pharmaceutical robot Dosell and sales of the medical device Pilloxa. Pilloxa AB was acquired on November 28, 2022 and therefore is not included in the revenue for the same quarter of the previous year.
The operating profit for the quarter amounted to -5,051 (-6,984) TSEK.
The profit after financial items for the quarter amounted to -5,187 (-7,032) TSEK.
The cash flow for the period amounted to 13,827 (-6,987) TSEK. The cash flow for the period includes a rights issue which raised approximately 18.6 MSEK for the company after issuance costs.
Earnings per share for the quarter before/after dilution amounted to 0.0 (-0.1) SEK.
The equity per share at the end of the period amounted to 0.2 (0.5) SEK.
The equity ratio at the end of the period amounted to 84.1 (80.8) percent.

Significant Events during the Quarter

iZafe has signed an exclusive partnership agreement with IVE Ventures for the right to exclusively sell and market the Dosell medication robot in the Netherlands. IVE has committed to purchasing at least 1,000 Dosell units annually for a three-year period to maintain exclusivity. The total value of hardware and license revenue amounts to approximately SEK 16 million during the first three years, followed by a recurring license revenue of at least SEK 6 million annually.
iZafe has signed an exclusive partnership agreement with UK-based Targeted Outcomes for the right to sell and market the Dosell medication robot in the UK for five years. Targeted Outcomes' minimum commitment over a five-year period amounts to SEK 18.7 million, followed by a recurring license revenue of at least SEK 7.9 million annually.
iZafe's subsidiary Pilloxa has signed a collaboration agreement with Chiesi in Germany worth SEK 1 million. The goal of the initiative is to give patients the opportunity to take control of their treatment journey and improve their quality of life. Pilloxa's app allows patients to track and record their medication and symptoms, set reminders, and generate reports to share with healthcare providers.
In March, iZafe announced the utilization of series TO13B subscription options, which were issued during the fourth quarter of 2022. A total of 96,805,841 series TO13B subscription options, equivalent to approximately 81.7 percent of outstanding series TO13B subscription options, were utilized to subscribe for 96,805,841 B shares at a subscription price of SEK 0.20 per B share. Through the utilization of the series TO13B subscription options, iZafe Group is adding approximately SEK 19.4 million before issuance costs.

Significant events after the end of the quarter.

iZafe has signed a cooperation agreement with Spanish company Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi's minimum commitment over a four-year period is worth at least 12 million SEK.
iZafe has signed a cooperation agreement with MDM Pulse for the right to sell and market the medication robot Dosell in Portugal. MDM Pulse's minimum commitment over a five-year period amounts to 12.2 million SEK, and thereafter generates a recurring license revenue of at least 4.2 million SEK annually.

Comments from CEO
I am pleased to present a quarterly report where we can show that we have further strengthened our positions and streamlined the organization within iZafe Group.
During the last quarter, we have worked hard to integrate Pilloxa into the organization, and I am proud to announce that we have retained Helena Rönnqvist, who was previously the CEO of Pilloxa, and appointed her as the company's Chief Medical Officer and Business Unit Manager for Pilloxa. At the same time, we have ended the employment of other personnel since we have been able to include their tasks into the existing personnel in iZafe Group. Therefore, we have paid out the remaining salaries, repaid loans, and debts that were in Pilloxa. At the same time, we have managed to reduce our costs, which will be even more evident in the upcoming quarter when the entire iZafe group, including Pilloxa, has scaled down costs.

During the beginning of this year, iZafe Group has signed cooperation agreements with several partners throughout Europe. We have established ourselves as a leading innovator in digital medication solutions, and our collaborations show the strength of Dosell and Pilloxa's innovative technology and its potential to improve the medication process for both patients and healthcare professionals worldwide.

The total value of all agreements amounts to over SEK 59 million, and the revenue from these agreements will gradually grow through monthly license income. We do not yet see the results of these significant agreements signed on the revenue line. I understand that it requires patience for you shareholders; adjustments and implementations take time, and we work every day to start our new collaborations as time-efficiently as possible.
Together, we can rejoice in a bright future where we have better opportunities than ever to enable safe and secure medication for many.

The most important parts going forward are to ensure that we can keep up with the production and integration work schedules. It will be tough since we are a small organization that needs to ensure a lot, but I am working with an incredibly dedicated team and feel confident that we will manage it.

We have had a fantastic outcome in the TO13B option program where we raised a total of SEK 19.4 million before issuance costs. With this money, reduced costs, and commitments from our new cooperation partners, these liquid assets are projected to last until we become cash flow positive.
We have also gained strong shareholders in the company who support and believe in us over the long term.
We have removed the exclusive sales of Dosell via Apoteket.se and initiated discussions to sell via more channels. Dosell as a consumer product is initially sold via Dosell's own website before gradually being sold through more players.

I am convinced that with strong growth in the global pharmaceutical market and an increased demand for digital medication solutions, iZafe Group is well positioned to continue its international expansion and revolutionize the pharmaceutical industry on a global level. We look forward to continuing to deliver positive results to our shareholders and partners.

Thank you for your continued trust.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

IZafe Group Q1 2023 ENG

iZafe Groups kvartalsrapport Q1, januari-mars 2023

iZafe Group AB (publ.) presenterar idag, 12 maj, sin rapport för det första kvartalet.

Finansiell utveckling i sammandrag

Nettoomsättningen för kvartalet uppgick till 228 (376) TSEK. Kvartalets omsättning utgörs av intäkter hänförliga till försäljning av den digitala läkemedelsroboten Dosell samt av försäljning av det medicintekniska hjälpmedlet Pilloxa. Pilloxa AB förvärvades den 28 november 2022 och ingår därför inte i kvartalets omsättning för föregående år.
Rörelseresultat för kvartalet uppgick till -5 051 (-6 984) TSEK.
Resultat efter finansiella poster för kvartalet uppgick till -5 187 (-7 032) TSEK.
Periodens kassaflöde uppgick till 13 827 (-6 987) TSEK. Periodens kassaflöde inkluderar emission med stöd av teckningsrätter vilken tillfört bolaget cirka 18,6 MSEK efter emissionskostnader.
Resultat per aktie för kvartalet före / efter utspädning uppgick till 0,0 (-0,1) SEK.
Eget kapital per aktie uppgick vid periodens slut till 0,2 (0,5) SEK.
Soliditeten vid periodens slut uppgick till 84,1 (80,8) procent.

Väsentliga händelser under kvartalet

iZafe har tecknat ett exklusivt samarbetsavtal med IVE Ventures för rättigheten att exklusivt sälja och marknadsföra läkemedelsroboten Dosell i Nederländerna. IVE har förbundit sig att köpa minst 1 000 Dosell årligen under en treårsperiod för att behålla exklusiviteten. Det totala värdet för köp av hårdvara och licensintäkter uppgår sammantaget till ca 16 MSEK under de första tre åren för att därefter generera en återkommande licensintäkt på minst 6 MSEK årligen.
iZafe har tecknat ett exklusivt samarbetsavtal med brittiska Targeted Outcomes för rättigheten att sälja och marknadsföra läkemedelsroboten Dosell i Storbritannien under 5 år. Targeted Outcomes minimumåtagande under en femårsperiod uppgår till 18,7 MSEK för att därefter generera en återkommande licensintäkt på minst 7,9 MSEK årligen.
iZafes dotterbolag Pilloxa signerar samarbetsavtal med Chiesi i Tyskland med ett värde på 1 MSEK. Målet med initiativet är att ge patienter möjlighet att ta kontroll över sin behandlingsresa och förbättra sin livskvalitet. Pilloxas app låter patienter följa och registreraspåra sin medicinering och symptom, sätta påminnelser och generera rapporter att dela med vårdgivare.
Under mars meddelade iZafe hur nyttjandet av teckningsoptionerna av serie TO13B blev, dessa emitterades under det fjärde kvartalet 2022. Totalt nyttjades 96 805 841 teckningsoptioner av serie TO13B, motsvarande cirka 81,7 procent av utestående teckningsoptioner av serie TO13B, för teckning av 96 805 841 B-aktier till en teckningskurs om 0,20 SEK per B-aktie. Genom nyttjandet av teckningsoptionerna av serie TO13B tillförs iZafe Group cirka 19,4 MSEK före emissionskostnader.

Väsentliga händelser efter kvartalets utgång

iZafe har tecknat ett samarbetsavtal med spanska Ti-Medi för rättigheterna att sälja och marknadsföra medicineringsroboten Dosell. Ti-Medis minsta åtagande över en fyraårsperiod är värt minst 12 MSEK.
iZafe har tecknat ett samarbetsavtal med MDM Pulse för rättigheten att sälja och marknadsföra läkemedelsroboten Dosell i Portugal. MDM Pulse minimumåtagande under en femårsperiod uppgår till 12,2 MSEK för att därefter generera en återkommande licensintäkt på minst 4,2 MSEK årligen.

Kommentar från VD
Jag är glad att kunna presentera en kvartalsrapport där vi kan visa på att vi stärkt våra positioner ytterligare och effektiviserat organisationen inom iZafe Group.
Under det senaste kvartalet har vi arbetat hårt för att integrera Pilloxa i organisationen, och jag är stolt över att meddela att vi har behållit Helena Rönnqvist som tidigare var VD för Pilloxa och utsett henne som bolagets Chief Medical Officer samt Business Unit Manager för Pilloxa. Samtidigt har vi avslutat anställningarna av övrig personal eftersom vi har kunnat inkludera deras arbetsuppgifter till redan befintlig personal i iZafe Group. Vi har därmed betalat ut övriga slutlöner, återbetalat lån och skulder som låg i Pilloxa. Samtidigt har vi lyckats sänka våra kostnader, vilket kommer att synas ännu tydligare i kommande kvartal då hela iZafe-koncernen inklusive Pilloxa har skalat ner kostnaderna.

Under starten av detta år har iZafe Group tecknat samarbetsavtal med flera partners runtom i Europa. Vi har etablerat oss som en ledande innovatör inom digitala medicineringslösningar, och våra samarbeten visar på styrkan i Dosell och Pilloxas innovativa teknologi och dess potential att förbättra medicineringsprocessen för både patienter och vårdpersonal runtom i världen.

Totalt uppgår värdet på samtliga avtal till över 59 miljoner kronor, och omsättningen från dessa avtal kommer att växa successivt via licensintäkter varje månad. Vi ser ännu inte resultatet av att dessa betydelsefulla avtal signerats på intäktsraden. Jag förstår att det är tålamodskrävande för er aktieägare; anpassningar och implementeringar tar tid och vi jobbar varje dag för att starta våra nya samarbeten så tidseffektivt som möjligt.
Vi kan tillsammans glädjas åt en ljus framtid där vi har godare förutsättningar än någonsin att på bred front kunna möjliggöra en säker och trygg medicinering för många.

De viktigaste delarna nu framåt blir att säkerställa att vi kan hålla tidsplanerna med produktion och integrationsarbeten. Det kommer vara tufft då vi är en liten organisation som ska säkerställa väldigt mycket, men jag jobbar med ett otroligt dedikerat team och känner mig trygg i att vi ska klara det.

Vi har fått ett fantastiskt utfall i optionsprogrammet TO13B där vi fick in hela 19,4MSEK innan emissionskostnader. Med dessa pengar, sänkta kostnader och åtaganden från våra nya samarbetspartners, prognoseras dessa likvida medel räcka tills vi blir kassaflödespositiva. Vi har även fått starka ägare till bolaget som stöttar och tror på oss över lång sikt. Vi har tagit bort exklusiv försäljning av Dosell via Apoteket.se och inlett samtal för att sälja via fler kanaler. Dosell som konsumentprodukt säljs inledningsvis via Dosells egen hemsida, innan den successivt säljs via fler aktörer.

Jag är övertygad om att med en stark tillväxt inom den globala läkemedelsmarknaden och en ökad efterfrågan på digitala medicineringslösningar är iZafe Group väl positionerade att fortsätta sin internationella expansion och revolutionera läkemedelsbranschen på global nivå. Vi ser fram emot att fortsätta att leverera positiva resultat till våra aktieägare och partners.

Tack för ert fortsatta förtroende.

Om iZafe Group AB (publ.)

IZafe Group Q1 2023

iZafe opens up more sales channels for Dosell consumer

iZafe Group AB ("iZafe Group") announces today that they are now removing exclusive sales of Dosell via Apoteket.se and are instead opening up to future sales via several sales channels. This after receiving great international impact for their pharmaceutical robot and now having volume commitments from several countries, including the UK, Holland, Portugal and Spain.

iZafe has also started dialogues with several pharmacies regarding selling Dosell as a consumer product and will therefore initially sell Dosell on its own website Dosell.se, before it is gradually sold via more partners. The introductory offer on the hardware remains SEK 499 until the last of May, before the price is raised to SEK 1,999. The monthly fee of SEK 299 will be maintained.

"The launch of the consumer version has been a determining factor in being able to sign the partners we have now started this year with. We are very happy about the great international interest for Dosell and look forward to opening up more sales channels. Our goal is to make Dosell available to as many people as possible who need help managing their medication." says Anders Segerström, CEO of iZafe Group.

For more information about Dosell, visit Dosell.se.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe opens up more sales channels for Dosell consumer

iZafe Group signs agreement with Ti-Medi in Spain worth minimum of SEK 12 million

iZafe Group AB ("iZafe Group") is pleased to announce that it has signed a collaboration agreement with Ti-Medi for the rights to sell and market the medication robot Dosell. Ti-Medi's minimum commitment over a four-year period is worth minimum SEK 12 million.

The first phase of the collaboration will start in October 2023, with the aim of ensuring the entire sales process and launching a unique concept from January 2024. The commitment is to sell at least 1,800 Dosell devices over four years. The revenue will gradually increase from the license revenue generated in connection with the launch in January 2024.

Ti-Medi is a global company that manufactures and distributes technical solutions for medication management compliance. Ti-Medi sells dose packaging machines to over 650 pharmacies in Spain and Portugal.

"We are pleased to welcome Ti-Medi as both a major shareholder and now also as a partner. Their broad experience in the pharmaceutical industry and their strong presence in the market make them an ideal partner to expand our sales of Dosell," says Anders Segerström, CEO of iZafe Group.

Over the last ten years, Ti-Medi has delivered technological solutions to healthcare professionals to make the management of Multi-Dosage Systems easier, safer, and more efficient. Currently, the company aims to offer technological solutions to patients as well.

"One in every two patients does not take their medication properly! We are pharmacists, and we truly believe in the role of the community pharmacy as a key player in the medication compliance challenge we are currently facing. With this partnership with Dosell, we aim to extend our value proposition to the end-patient, improving their quality of life by making it easier to manage their medication," says Marc Tarruell, Co-Founder of Ti-Medi.

For more information, please visit Ti-Medi's website, www.ti-medi.com/en.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group signs agreement with Ti-Medi in Spain worth minimum of SEK 12 million